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Abstract 
Extracellular matrix (ECM) is a dynamic network of macromolecules, playing a regulatory role in cell 
functions, tissue regeneration and remodeling. Wound healing is a tissue repair process necessary for 
the maintenance of the functionality of tissues and organs. This highly orchestrated process is divided 
into four temporally overlapping phases, including hemostasis, inflammation, proliferation and tissue 
remodeling. The dynamic interplay between ECM and resident cells exerts its critical role  in many 
aspects of wound healing, including cell proliferation, migration, differentiation, survival, matrix 
degradation and biosynthesis. Several epigenetic regulatory factors, such as the endogenous non-coding 
microRNAs (miRNAs), are the drivers of the wound healing response. microRNAs have pivotal roles in 
regulating ECM composition during wound healing and dermal regeneration.Their expression is 
associated with the distinct phases of wound healing, and they serveas target biomarkers and targets for 
systematic regulation of wound repair. In this article we critically present the importance of epigenetics 
with particular emphasis on miRNAs regulating ECM components (i.e. glycoproteins, proteoglycans and 
matrix proteases) that are key players in wound healing. The clinical relevance of miRNA targeting as  
well as the delivery strategies designed for clinical applications are also presented and discussed. 
  
 
 
Extracellular matrix: a dynamic regulatory network 
Extracellular matrix (ECM) is the non-cellular highly organized three-dimensional meshwork that is 
formed by a variety of interconnected matrix macromolecules ECM vigorously interacts with cells to 
control cellular phenotype and properties [1, 2]. Collagens, fibronectin, elastin, laminins, proteoglycans 
(PGs), hyaluronan (HA), glycoproteins and matricellular proteins are among the major ECM components. 
Two subtypes of ECM named interstitial and pericellular ECMs can be distinguished in regard to their 
localization and structure. Interstitial matrix encompasses cells, whereas pericellular matrix encircles 
cells in close contact, supporting their anchorage. Interstitial matrix is dominated by fibrillar collagens, 
such as collagen I and III, PGs, HA and several matrix glycoproteins [1, 2]. An example of pericellular 
matrix is the basement membrane that underlies epithelial cells, which provides many binding sites to 
mediate their strong docking. It is enriched in collagen IV and laminins, which that form two distinct 
interconnected networks   by several molecular linkers, such as perlecan, a pericellular PG. 
All ECM constituents are produced by several cells resting within this scaffold, such as fibroblasts, 
epithelial, endothelial and immune cells, and their composition and fine structure differs in different 
types of ECM and between tissues. ECMs with different composition of matrix molecules can vary in 
regard to overall structure, matrix mechanical properties, stiffness and viscoelasticity providing tissues 
with distinct functionality [3]. Furthermore, ECM components like PGs are able to bind and store growth 
factors and other bioactive molecules creating a reservoir of such molecules within the ECM [3]. Resting 
cells interact with ECM molecules via binding through specific cell surface receptors such as integrins, 
cell-surface PGs, syndecans and glypicans, discoidin domain receptors (DDRs) and the HA receptor CD44, 
which binds a large variety of matrix components [2, 4-6]. By these interactions, matrix-embedded cells 
integrate mechanical and chemical signals that control cell fate and functions, such as cell phenotype, 
synthesis of matrix microenvironment, cell proliferation, migration, invasion and survival [7]. ECM 
composition and structure is crucial for tissue homeostasis, whereas active ECM remodeling occurs 
under physiological and pathological conditions. ECM degradation is a crucial process in tissue 
remodeling. A huge variety of degrading enzymes is involved in matrix breakdown, such as matrix 
metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAMs), ADAMs with 
thrombospondin motifs (ADAMTs), cathepsins, plasminogen activators, and glycosaminoglycan (GAG) 
degrading enzymes like hyaluronidases and heparanase (HPSE) that cleave HA and heparan sulfate (HS) 
chains, respectively [8-11]. These enzymes not only actively degrade matrix during remodeling by 
creating space for new ECM formation by resident cells, they also liberate bioactive molecules, such as 
growth  factors  stored  within  ECM   as  well  as   proteolytic  fragments  of  matrix  molecules      named 
  
 
 
matrikines [8, 12, 13]. In turn, these molecules could bind to cell surface receptors on resident cells and 
regulate their functions and matrix remodeling. Accumulating data on the dynamic interplay between 
ECM and resident cells confirm its critical role in wound healing [1, 2, 8, 13]. For example, recessive 
dystrophic epidermolysis bullosa caused by mutations in the collagen VII α1 chain is associated with 
dysregulated wound healing. Collagen VII is responsible for the anchorage of the epidermis to the 
underlying dermis and patients with this disease suffer from blistering and chronic wounds leading to 
fibrosis and are prone to develop squamous cell carcinoma [14]. In another example, defective epithelial 
basement membrane regeneration after injury associated with abnormal deposition of laminin and 
nidogen is related to corneal fibrosis [15]. Abnormal expression of cell surface PGs such as syndecans is 
also associated with irregular wound healing in animal models. Mice lacking syndecans exhibit  
decreased pro-fibrotic signaling, affected wound healing and increased cardiac rupture upon infarction 
demonstrating a key role for these PGs in tissue repair [16]. 
 
Wound healing phases and the involvement of extracellular matrix 
Wound healing is an essential and highly orchestrated process, necessary to keep the integrity and 
functionality of tissues and organs [8,13,14]. In this well-regulated dynamic process, several cell types 
that cooperate with ECM components in a time- and context-dependent manner contribute to re- 
establish the wounded tissue. This dynamic reciprocity between cells and ECM plays a crucial role in 
many aspects of healing [14]. Although most wounds heal nearly properly and tissues regain the pro- 
wound functionality, abnormal wound healing occurs, resulting in non-healing wounds and the 
development of chronic wounds, or in excessive wound healing and fibrosis. The development of  
chronic wounds is often associated with other comorbidities, such as diabetes and aging. On the other 
hand, excessive healing leads to fibrosis and development of hypertrophic scars and keloids in skin [13- 
15]. 
Wound healing is parsed into four temporally overlapping stages, named hemostatic, inflammatory, 
proliferation and remodeling phases, which occur at different rates across the wound (Figure 1). 
Immediately after tissue injury, the hemostatic phase begins and the coagulation cascade is activated to 
seal the breach and impede infection. This phase is followed by the inflammatory phase where the 
activation of the coagulation cascade induces the production of cytokines and growth factors and the 
recruitment of inflammatory cells. Inflammation induces the migration and proliferation of stromal cells 
within the wound bed, the formation of granulation tissue and neovascularization during the 
proliferation phase. Contraction of newly formed ECM by myofibroblasts and re-epithelialization  occurs 
  
 
 
at this phase to restore tissue integrity and reduce wound size. Finally, the remodeling phase is 
characterized by a decrease in the overall number of cells and vessels within wounded bed and the 
replacement of newly produced matrix with a mature ECM with proper mechanical properties. 
The hemostatic phase initiates the coagulation cascade to seal the rupture. Particularly, once the tissue 
is damaged, the initiation of coagulation cascade starts and platelets accumulate in a provisional matrix 
composed of fibrinogen, fibrin, fibronectin and vitronectin. Fibrinogen is a plasma glycoprotein that is 
cleaved by α-thrombin to fibrin monomers that spontaneously form insoluble fibrin polymers. They are 
subsequently cross-linked by factor XIIIα to create a more stable clot that stems blood loss and provides 
a platform for tissue repair [13,14]. Factor XIIIα also facilitates the incorporation of soluble fibronectin 
into the fibrin network. Both fibrin/fibrinogen and fibronectin as well as vitronectin are capable of 
interacting with platelets, immune cells, fibroblasts, endothelial cells, keratinocytes via cell surface 
receptors such as integrins and cell surface PGs regulating cell signaling, adhesion, migration, 
proliferation and differentiation [7, 17-19]. In addition, they bind growth factors, such as platelet  
derived growth factor (PDGF), transforming growth factor beta (TGF-β), fibroblast growth factor (FGF), 
vascular growth factor (VEGF), thus providing a milieu that can control cell fate and functions [17]. 
During this phase, HA accumulates in early granulation tissue Through binding to fibrinogen, it realigns 
the fibrin matrix causing it to swell and rendering it more porous, thus facilitating cell migration [20] 
(Figure 1). The next step, the inflammatory phase, is characterized by recruitment of immune cells into 
the wounded area and it is followed by the subsequent proliferation phase where damaged tissue is 
replaced. In the inflammatory phase, approximately a day post wounding, leukocytes migrate into the 
wound site and the fibrin-rich provisional matrix, attracted by platelet-released PDGF and TGF-β [17]. 
HSPGs on endothelial cells facilitate the infiltration of leukocytes into wound areas [21]. Neutrophils and 
macrophages serve to limit infection and to remove cell debris and foreign material through 
phagocytosis. Leukocytes release proteases to degrade ECM such as neutrophil elastase that break  
down molecules suppressing angiogenesis, and MMPs that degrade several matrix components, such as 
collagen I, thereby facilitating cell migration [22-25]. Furthermore, they release matrix-stored growth 
factors and cytokines as well as matrikines able to regulate multiple cell functions during the 
inflammatory process. Matrix PGs such as decorin and lumican that suppress growth factor induced 
signaling are also displaced in this phase [5]. Infiltrating immune cells secrete several inflammatory 
mediators and growth factors such as PDGF, epidermal growth factor (EGF) and TGF-β to promote 
further the recruitment of inflammatory cells and to attract stromal cells to the wound bed [17] (Figure 
1). In the proliferation phase,         inflammation starts to decrease two to three days post wounding and 
  
 
 
stromal cells migrate into the wound area, attracted by growth factors such as FGF secreted by 
inflammatory cells. There, migrated fibroblasts prime the matrix for immigration and proliferation of 
various cellular components under the control of growth factors such as TGF-β released by platelets and 
leukocytes [17]. TGF-β triggers fibroblasts to create a provisional ECM enriched in fibronectin, 
matricellular proteins such as tenascin and thrombospondin, entactin, collagen and PG with both 
adhesive and anti-adhesive properties that promotes the migration of endothelial and epithelial cells, 
keratinocytes and fibroblasts [19, 26-28]. The new matrix production is accompanied by decreased 
synthesis of MMPs and initiation of epithelial cell migration under the control of EGF and TGF-α 
produced by platelets, leukocytes and keratinocytes [29]. As the fibroblasts immigrate and settle in the 
wound bed, they start to produce a fibrous ECM enriched in fibrillar collagen III and I, and non-fibrillar 
collagen IV, VI and VII that interconnect ECM molecules with fibrillar collagens [13, 17]. Fibronectin acts 
as scaffold for collagen deposition and PGs such as decorin and lumican, which are re-expressed at this 
stage, contribute to fibrillar collagen organization creating a collagen-rich matrix that replaces fibrin-rich 
matrix [5, 13, 30, 31]. The small leucine rich PGs (SLRPs) decorin and lumican also limit cell signaling by 
suppressing the activation of numerous growth factor receptors, and by directly binding and blocking 
growth factors to reduce excessive cell proliferation and migration [5]. Fibrillar collagens are responsible 
to provide new matrix with tensile strength, whereas collagen IV is important for attachment of ECM to 
vasculature. In skin, keratinocytes migrate to re-epithelialize the wound are and contact-inhibited 
keratinocytes behind the leading edge participate in the production of laminins and collagen IV that 
reconstitute the basement membrane where they are strongly anchored by hemidesmosomes [13]. 
Finally, the remodeling phase is responsible for wound resolution and restoration of proper functional 
tissue (Figure 1). The aim of this phase that may last up to one or more years is to replace the wounded 
tissue with scar tissue that will be covered by new epithelium. During this phase, the granular tissue is 
replaced by mature ECM. The provisional supportive ECM enriched in matricellular proteins and collagen 
III is substituted by a collagen I-rich matrix with SLRPs playing a role in mature fibril formation [5, 32]. A 
continuous collagen synthesis and degradation occurs and collagen fibers realign, cross-linked and 
increase in diameter to form mature and well-organized fibers with increased tensile strength. Stromal 
cells are triggered by the stiffer matrix and TGF-β to adopt a myofibroblast phenotype. In turn, these 
cells produce more collagen and induce wound contraction [33, 34]. At the same time, apoptosis of 
excess cell populations increases, that is accompanied by completion of new vessel formation. The end 
of the wound healing process results in a scar tissue with overly aligned collagen fibers that regain 
almost 80% of the original tissue strength and functionality [13]. 
  
 
 
 
Extracellular matrix components and their roles in would healing 
Proteins/glycoproteins 
The collagen superfamily consists of 28 different collagen types with collagen type I and III being the two 
major types found in all interstitial ECMs [2]. Although collagen fibers provide appropriate strength in 
wounded tissue, the excessive production of tight collagen bundles is a factor that contributes to the 
development of hypertrophic scars [32]. It has been shown that the mechanical properties of the ECM 
regulate functional properties of fibroblasts including biosynthesis of ECM components, expression of 
MMPs as well as their differentiation to myofibroblasts even independently of TGF-β signaling [35-38]. 
The expression of different amounts and types of collagens during wound healing is critical. Apart from 
determining matrix stiffness, collagens regulate fibroblast functions relevant to wound repair. It has 
been shown that collagen III regulates collagen I synthesis, and a higher ratio of collagen III to collagen I 
is associated with scarless fetal wound healing in various models, whereas its absence promotes 
myofibroblast differentiation and scar formation [32, 39, 40]. Similarly, the absence of collagen V results 
in abnormal collagen I fibril formation since it is required for proper collagen fibrillogenesis and 
functional matrix deposition [41, 42]. Another collagen that is involved in tissue repair is collagen VI that 
is detected in wounds three days post wounding up to months and inhibits the apoptosis of fibroblasts 
via downregulation of Bax [43]. Collagen VII plays a dual role in wound healing It  facilitates  the 
migration of fibroblasts and regulates the expression of cytokines in macrophages [44]. Furthermore, 
collagen VII is required for re-epithelialization through organization of laminin-332 at the dermal- 
epidermal junction, which in turn promotes the polarized expression of α6β4 integrin in basal 
keratinocytes, thus promoting laminin-332/ α6β4 integrin signaling that guides keratinocyte migration 
[44]. Exogenous addition of collagen VII into skin wounds decreased the expression of fibrogenic TGF-β2 
and increased the expression of anti-fibrogenic TGF-β3, resulting in less collagen deposition and 
prevention of fibrosis [45]. Furthermore, patients with recessive dystrophic epidermolysis bullosa  
caused by mutations that affect the amount or/and the function of collagen VII are characterized by 
chronic non-healing wounds, persistent inflammation, increased TGF-β signaling, elevated number of 
myofibroblasts and development of fibrosis [14]. 
Fibronectin is another ubiquitous component of ECM in the wound bed. It is a glycoprotein consisting of 
two subunits covalently connected with disulfide bonds at their C-termini. Each subunit consists of three 
repeating modules termed type I, type II and type III. Monomers are comprised of twelve type I repeats, 
two type II repeats and 15-17 type III repeats [2, 19]. Due to alternative splicing, fibronectin can exist   in 
  
 
multiple variants that can be found in soluble form in plasma or in an insoluble cellular form in the ECM. 
Cellular fibronectin contains two extra type III repeats named extra domain A (EDA) and extra domain B 
(EDB) [19]. Fibronectin is assembled into supermolecular fibers that are interconnected by 
intermolecular non-covalent bonds forming an extended network. Cells produce new fibronectin 
molecules to fibronectin fibers that are incorporated and grow the network. Alternatively, cells can 
assemble soluble plasma fibronectin into insoluble fibers in the wound. Fibronectin is covalently 
connected to fibrin fibers and factor XIII further stabilizes this interaction [2, 19, 32]. Fibronectin 
entrapped within the provisional fibrin-rich matrix undergoes conformational changes that expose (Arg- 
Gly-Asp) RGD cell binding sites for αvβ3 integrins on fibroblasts, thus promoting their migration into the 
wound [32]. Furthermore, fibronectin possess many binding sites for cells and other ECM components, 
creating a provisional matrix that controls cellular properties and matrix deposition. It has been shown 
that a fibronectin matrix is required for deposition of collagen I and III and other matrix components 
such as fibrillin, tenascin-C, fibulin and latent TGF-β binding protein [46-53]. In addition, it controls 
covalent cross-linking of fibrillar collagens and elastin by regulating the proteolytic activation of lysyl 
oxidase [54]. Fibronectin matrix fibers can also bind growth factors, such as PDGF, VEGF, FGF, TGF-β 
members creating a matrix reservoir for these molecules. They can penetrate and bind to fibronectin 
fibers, protected from proteolytic degradation and creating a stable concentration gradient within the 
ECM. They may be liberated upon ECM degradation or may be available to interact with cell surface 
receptors upon cell binding to fibronectin fibers, thus triggering signaling in neighboring or adherent 
cells [19]. Fibronectin accumulation is also associated with abnormal wound healing and fibrosis. 
Expression of a fibronectin splice variant containing EDA (Fn-EDA) is increased during wound healing and 
its level is decreased as myofibroblasts synthesize collagen I-rich matrix and declines almost completely 
in adult tissues [17, 55]. Fn-EDA is abundant in keloids and it has been associated with altered integrin 
binding and development of fibrosis [26, 56]. Fn-EDA is susceptible to mechanical forces that cause 
conformational changes to destabilize the RGD and Pro-His-Ser-Arg-Asn (PHSRN) binding sites, resulting 
in an integrin binding "switch". Binding of α5β1, α3β1 integrins to fibronectin depends on fibronectin 
conformation and is correlated with wound repair, whereas binding of αv integrins is independent of 
fibronectin conformation and is associated with abnormal wound healing and fibrosis [17]. Fibroblasts 
bind to Fn-EDA via α4β7 and α4β1 integrin to promote fibronectin and collagen deposition, a contractile 
phenotype and fibrosis [57, 58]. The role of Fn-EDA in normal and pathologic wound healing has been 
demonstrated  in  Fn-EDA-/-   mice  that  show  a  lack  of  scar  formation  and  re-epithelialization  [59]. In 
  
 
 
addition, toll-like receptor 4 (TLR4) binds Fn-EDA, triggering TGF-β production and establishment of a 
vicious cycle of fibrosis [56, 60, 61]. 
Vitronectin is another important ECM molecule related to wound healing. It acts in co-operation with 
fibronectin regulating fibroblastmigration and contraction. In order to contract a wound with full force, 
fibroblasts require to attach sequentially to fibronectin, vitronectin and collagen [62]. In addition, 
vitronectin controls the proliferative and migratory effect of fibronectin on fibroblasts by inducing 
conformational alterations on fibronectin fibrils and concealing RGD sequences. This reduces binding of 
αvβ3 integrins on fibroblasts and balances their fibronectin-induced proliferation and migration , 
exerting a pro-fibrotic effect in early phases of wound healing [32, 63]. 
Elastin fibers provide resilience and elasticity to tissues, which undergo repeated stretching and are 
intertwined with the rigid collagen fibers. Several proteolytic enzymes degrade elastin and liberate 
elastin-derived peptides that promote keratinocyte migration, an angiogenic endothelial cell  angiogenic 
, fibroblast proliferation, induction of MMP expression and deposition of collagen I and tropoelastin  
[64]. Laminins (LAMs) are major components of basement membranes and are large cross-shaped 
heterotrimeric glycoproteins. Each heterotrimer consists of one α, one β and one γ chain. Five α 
(LAMA1-5), three β (LAMB1-3) and three γ chains (LAMC1-3) encoded by individual genes have been 
identified. Two isoforms of the LAMA3 gene produce a short α3A and a longer α3B form. Laminins are 
named according to their chain composition. For example laminin 332 consists of the α3, β3 and γ3 
chain [2, 65]. Laminin molecules self-assemble into higher order networks and interact with other ECM 
molecules and cell surface receptors to organize basement membrane structure and to facilitate cell 
adhesion and migration. Laminins are involved in re-epithelialization and angiogenesis during wound 
repair [2, 65]. The major laminin in epithelial tissues is laminin α3Aβ3γ2 (LM3A32 or LM332), whereas 
minor amounts of other laminins such as LM511, LM3A11, and LM3B32 are also present [65]. LM332 is 
first expressed by keratinocytes in the wound bed, followed by the expression of other basement 
membrane molecules, including LM511/LM521, collagen IV and VII [65-68]. Keratinocytes interact with 
LM332 through α6β4 integrin in the intermediate filament associated hemidesmosome and α3β1 
integrin in the actin filament-based focal adhesion. Both stable and transient interactions are required 
for directional persistence in keratinocyte migration and wound closure [65]. Inherited diseases such as 
junctional epidermolysis bullosa and laryngo-onycho-cutaneous syndrome which are associated with 
mutations in all chains of LM332 and mutations in the α3 chain, respectively, are characterized by 
excessive granulation tissue and chronic, slow-healing cutaneous erosions [69, 70]. Other minor laminins 
  
 
 
play also important roles in wound healing. For example, it has been shown that reduced expression of 
LM111 and LM511 in corneal basement membranes of patients with diabetes is associated with delayed 
corneal epithelial wound closure [71]. The α5 laminin chain displays an increased ability to interact with 
cell surface receptors on endothelial cells and keratinocytes. LM511 co-operates with LM332 to support 
directional migration in epithelial cells [65, 72]. Laminins are also involved in blood vessel growth and 
maturation, a major process associated with wound healing. LM411 predominates in endothelial 
basement membranes with LM511 and LM3B11 being minor components in small vessels  [65].  
Although the α4 laminin chain has the lowest affinity for various cell surface receptors, it is critical for 
the proliferation, adhesion and migration of endothelial cells [65, 73, 74]. 
Matricellular proteins form a large class of modular proteins that can be found in the ECM, the inner 
plasma membrane and endoplasmic reticulum and in the nucleus participating in numerous cell 
functions [2, 28]. Matricellular proteins are minor components of adult tissues they exhibit increased 
expression in developing tissues as well as during pathologic processes including cancer, diabetes, 
hypertension, and wound healing [2, 28]. They bind to several matrix components, cell surface  
receptors, growth factors, cytokines and proteases controlling cell-cell and cell-matrix interactions. They 
are upregulated in the wound bed and it is believed that they do not contribute to ECM integrity, but  
are rather involved in the transient regulation of cell signaling, adhesion, migration and matrix 
biosynthesis. Matricellular proteins bind to and modulate signaling of soluble growth factors such as 
VEGF, FGF, and latent TGF-β . Notably, matricellular proteins can trigger growth factor receptor signaling 
both directly and indirectly [28]. For example, tenascin-X activates latent TGF-β via binding to cell  
surface α11β1 integrin and in turn promotes epithelial-to-mesenchymal transition (EMT) in mammary 
epithelial cells [75]. Thrombospondin 1 (TSP1) also activates latent TGF-β in cell-independent manner 
[76]. Matricellular proteins such as osteopontin, CCN2, TSP-1, and SPARC are also involved in 
development of fibrosis in patients suffering from metabolic diseases such as diabetes and obesity [77- 
83]. Osteopontin is involved in dermal fibrosis since it facilitates TGF-β-induced myofibroblast 
differentiation [84, 85]. It also augments fibroblast proliferation and migration and abrogation of its 
expression results in faster wound healing with less granulation tissue and scar formation [86, 87]. The 
matricellular protein CCN2 is also upregulated in the wound bed and its expression is associated with 
hypertrophic scarring and fibrosis [88, 89]. It stimulates the recruitment of differentiation of 
mesenchymal stem cells to fibroblasts in the wound bed. CCN2 also promotes fibroblast adhesion to 
fibronectin, as well as the expression of ECM molecules including collagen I, III, FGF and tissue inhibitors 
of MMPs (TIMPs) [90, 91]. In a recent study it has been shown that CCN2 induces cellular senescence  in 
  
 
 
fibroblasts that in turn adopt an anti-fibrotic "senescence-associated secretory phenotype" associated 
with upregulation of MMPs and downregulation of collagen, suggesting an anti-fibrotic role for CCN2 in  
a context-dependent manner [92]. Furthermore, CCN2 is also involved in re-epithelialization by 
promoting keratinocyte migration via interaction with α5β1 integrins [93]. SPARC is another 
matricellular protein upregulated in wounds and it is associated with the development of fibrosis. It 
promotes the biosynthesis of ECM molecules and collagen fibrillogenesis in dermal fibroblasts [94-96]. 
Another matricellular protein associated with fibrosis is periostin, which is accumulated in fibrotic 
dermis. Periostin supports Rho-associated protein kinase-dependent proliferation and myofibroblast 
persistence of hypertrophic scar fibroblasts, but not of normal dermal fibroblasts [97]. Tenascin-C is 
accumulated in wound edges promoting the migration of fibroblasts along fibrin-fibronectin rich 
matrices in early wounds. In contrast, degradation of tenascin-C in later stages of wound healing 
liberates fragments that inhibit the migration of fibroblasts [98, 99]. This dual role of tenascin-C seems 
to buffer fibroblast functions. The association of tenascin-C accumulation with fibrotic disease may be a 
result of persistent expression of tenascin-C, or a failure of its degradation by matrix proteases [100, 
101]. 
 
Proteoglycans and hyaluronan 
PGs are complex macromolecules consisting of a core protein to which one or more GAG chains are 
covalently attached. GAGs are long heteropolysaccharides that contain repeating disaccharide units 
composed of hexuronic acids (D-glucuronic acid or L-iduronic acid) and hexosamines (N-acetyl-D- 
galactosamine or N-acetyl-D-glucosamine) [100,101]. These polymers can carry sulfate groups in various 
positions of uronic acids and hexosamines provid them with high structural heterogeneity and high 
negative charge. There are six types of GAGs named chondroitin sulfate (CS), dermatan sulfate (DS), HS 
and heparin, the non-hexuronic acid-containing keratan sulfate (KS) and HA which is the only GAG 
present in free form not covalently bound onto a PG core protein [102, 103]. PGs are extremely 
heterogeneous in nature since they can carry more than one types of GAG chains and these chains can 
vary in length and fine structure. PGs are capable of interacting with a plethora of ECM molecules, cell 
surface receptors, growth factors and cytokines, either via their GAG chains or through their  core 
protein thus regulating ECM organization, cell signaling, proliferation, adhesion, migration, survival and 
differentiation [102, 103]. According to their localization, PGs are divided to three categories: 
extracellular, cell surface and intracellular ones. Each PG category is then classified in subfamilies 
according to their protein sequence homology and the presence of unique protein modules [5, 103]. PGs 
  
 
 
are important molecules that regulate cell-matrix interactions and are actively implicated in the wound 
healing process [5, 103]. 
Versican belongs to a subfamily of matrix secreted PGs named hyalectans. It can interact with HA and 
other matrix components and cell surface receptors creating large complexes that retain large amounts 
of water creating a viscous ECM. It is a versatile molecule that regulates cell signaling and motility [18, 
103, 104]. Versican accumulates in hypertrophic burn scars and is produced in high amounts by deep 
dermal fibroblasts that are involved in the development of hypertrophic scars [105, 106]. Suppression of 
versican leads to a less aggressive growth of dermal papilla fibroblasts [107]. Furthermore, elevated 
levels of versican are associated with enhanced fibroblast migration and wound healing [108]. 
Another subfamily of matrix PGs are SLRPs. Decorin, biglycan and lumican are members of  this  
subfamily and it has been shown to be involved in wound healing. Decorin, biglycan and fibromodulin 
are accumulated in the wound bed and their levels are modified during wound healing [109]. Biglycan is 
highly expressed in hypertrophic burn scars, whereas the levels of decorin and fibromodulin were 
significantly lower in hypertrophic scars compared to normal skin [105, 110]. Decorin is expressed late 
during wound healing in burn scars [111]. In vivo experiments in decorin knockout mice demonstrated 
that decorin is important for cutaneous wound healing and its loss is associated with delayed wound 
healing [112], whereas decorin deficient fibroblasts demonstrate increased adhesion to collagen and 
fibronectin and enhanced rates of proliferation and migration [113]. It has been also shown in tendon 
injury that biglycan and decorin are critical for proper healing at younger ages. In aged mice, the 
presence of both molecules is beneficial only in early-stage healing and is inadequate to promote late- 
stage healing [114]. Decorin binds TGF-β acting as a natural inhibitor for this growth factor, thus 
buffering its function during wound healing and preventing fibrosis. Decorin transfection decreased the 
TGF-β-induced expression levels of profibrogenic genes such as fibronectin, collagen type I, III, and IV in 
corneal fibroblasts as well as their differentiation to myofibroblasts. Furthermore, SLRPs as decorin, 
lumican and fibromodulin play a critical role in collagen fibrillogenesis and proper architecture of 
collagen fibers [5, 103]. Their levels may be essential for proper organization of collagen fibers during 
normal wound healing whereas disturbance of their amounts may result in a less organized and fibrotic 
ECM observed in keloid tissue and hypertrophic burn scars [105, 115]. Lumican promotes fibroblast 
activation and contraction in an integrin α2-dependent mechanism [116]. Lumican-deficient mice exhibit 
delayed corneal and skin wound healing, abnormal collagen fibrils and fragile skin [117, 118]. The 
absence of lumican leads to decreased apoptosis of fibroblasts and keratocytes, reduced recruitment of 
macrophages and neutrophils and modulation of Fas-FasL signaling suggesting a role for lumican in 
  
 
 
fibrotic healing [117]. In addition, SLRPs can bind directly to various growth factors receptors such as 
EGFR, VEGFR2, IGF-IR and innate immune system receptors like TLRs modulating cell signaling, evoking 
autophagy and promoting the secretion of pro-inflammatory mediators involved in wound healing [119, 
120]. All these functions may differentially regulate excessive angiogenesis, cell proliferation and ECM 
production in the wound bed. 
Cell surface PGs are categorized mainly into two major subfamilies named syndecans and glypicans. 
Syndecans consist of four members and they are transmembrane PGs carrying mainly HS chains [119]. 
Through their HS chains, they can bind numerous ECM components, soluble ligands including 
interleukins, FGF, VEGF, TGF-β, Hedgehog and Wnt and may interact laterally with other receptors such 
as FGFR, EGFR, integrins and stretch-activated calcium channels of the TRPC family. So, syndecans can 
act as co-receptors for growth factors and ECM molecules promoting signaling and regulating a plethora 
of cell functions [6, 121, 122]. Syndecans are upregulated during tissue injury and play crucial roles in 
wound healing. Syndecan-1 and -4 are upregulated in skin wounds and are involved in re- 
epithelialization [123]. Syndecan-1 deficiency is associated with compromised adhesion, migration and 
differentiation of keratinocytes and delayed re-epithelialization [124, 125]. On the other hand, over- 
expression of syndecan-1 delays epidermal wound healing due to increased proteolytic shedding of 
syndecan-1 ectodomain that in turn inhibits cell proliferation [126]. Similarly, knockout of syndecan-4 
leads to delayed skin repair affecting fibroblasts migration, granulation tissue and angiogenesis, but also 
reduces the ability to exert tension on the ECM [127, 128]. Syndecans also regulate growth factor 
activities to promote wound healing. For example, when syndecan-4 is activated by FGF-2 augments 
wound healing by activating dermal fibroblasts adhesion and producing ECM [127]. Syndecan-4 binds 
tenascin-C and fibronectin, promoting wound healing in fibroblasts [129]. Both syndecan-2 and -4 co- 
operate with integrin α5β1 to bind a transglutaminase-fibronectin rich matrix and to induce cell 
adhesion and fibronectin deposition during epidermal wound healing [130]. Syndecan-1, via interaction 
with αvβ3 and αvβ5, promotes smooth muscle and endothelial cell activation and vasculature 
regeneration [131, 132]. Syndecan-1 and -4 knockout mice show functionally adverse infarct healing in 
the heart and syndecan deficiency is associated with less organized collagen fibers susceptible to MMP 
degradation, hampered granulation, attenuated myofibroblasts differentiation and contractility, that 
ultimately lead to cardiac dilatation and rupture [133, 134]. Both syndecan-1 and -4 are involved in the 
activation of pro-fibrotic signaling to cardiac fibroblasts inducing ECM production, matrix contraction, 
differentiation to myofibroblasts and heart fibrosis [16]. Activation of the renin-angiotensin-aldosterone 
system and production of angiotensin II is a potent pro-fibrotic signal that requires the presence of 
  
 
 
syndecan-1 to stimulate cardiac fibrosis by enhancing TGF-β signaling, biosynthesis of collagens and 
secretion of CCN2 [135]. On the other hand, the pro-fibrotic role of syndecan-4 is mediated by binding  
to calcineurin via its cytoplasmic domain and activation of calcineurin-nuclear factor of the activated T- 
cells (NFAT) signaling pathway to promote myofibroblast differentiation, collagen production and 
myocardial stiffness [136]. Syndecan-4 can also regulate the pro-fibrotic events in fibroblasts through 
inhibition of calcium influx via the transient receptor potential canonical (TRPC) 7 cell membrane 
channel. Syndecan-4 induces protein kinase Cα (PKCα) to phosphorylate TRPC7, thus controlling 
cytosolic calcium levels and myofibroblasts differentiation as well as keratinocytes adhesion and 
differentiation [137]. In contrast to its full-length form, syndecan-4 fragments shed from the cell surface 
upon the action of matrix-degrading enzymes inhibit the proliferation of cardiac fibroblasts, reduce the 
expression of collagen I and III and upregulate the ratio of MMPs to TIMPs to favor matrix degradation 
[138]. 
Serglycin represents the only characterized intracellular PG so far. Serglycin is localized into secretory 
granules of inflammatory cells and platelets, is secreted by dermal fibroblasts upon UVB exposure and is 
involved in tissue repair [139]. It is co-localized into α-granules of platelets with bioactive molecules 
including fibronectin, PDGF, CXCL7, CXCL4, RANTES/CCL5 and CCL3 and is essential for their storage and 
effective platelet aggregation and leukocyte activation [139, 140]. Apart from binding to inflammatory 
mediators and directing their bioavailability and functions within ECM, serglycin is also capable  of 
directly interacting with ECM molecules. It binds to collagen I and collagen-like structures of other 
proteins affecting cell functions and immune system response [141, 142]. This implies that serglycin is 
strongly implicated in the inflammatory phase of wound healing process, as well as in the tissue 
remodeling phase, since it mediates endothelial cells’ functions [143, 144]. 
HA is is synthesized by three HA synthases (HAS1-3) at the cytosolic part of the cell membrane in 
mammals [145]. HA has a dual role and is involved in both fibrotic and regenerative wound healing. For 
example, oral fibroblasts that promote rapid and scarless wound healing don't express HAS and have 
decreased pericellular HA amounts [146]. In contrast, fetal scarless wound healing is associated with 
increased amounts of HA, and in vitro treatment of adult wounds with amniotic fluid enriched in HA 
markedly improved re-epithelialization [147, 148]. It has been shown that HA of different size has 
opposite effects in various cellular functions and wound healing. Large molecular-weight HA is 
correlated with decreased inflammation, increased expression of collagen III and TGF-β3 activity that  
has anti-fibrotic action, whereas low molecular weight HA exhibits increased inflammation, collagen I 
synthesis,  increased  proliferation  of  fibroblasts  and  differentiation  to  myofibroblasts,  promoting   a 
  
 
 
fibrotic cell phenotype [149, 150]. Actually, at sites of inflammation low molecular weight HA binds to 
TLR2/4 and activates signaling cascades that promote the release of the pro-inflammatory cytokines 
interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), and IL-1β, that in turn stimulate HA production in 
various cell types [27, 151]. Accumulation of HA is observed in fibrosis and the failure to remove HA 
fragments by CD44 and TLRs contributes to persistence of inflammation and destruction observed in 
tissue fibrosis [152, 153]. Although HA binds to CD44 and RHAMM and signals through them, HA also 
seems to be essential for TGF-β-induced fibroblast differentiation into myofibroblasts [154-156]. It is 
suggested that HA regulates TGF-β signaling by inducing a co-localization and interaction of the 
receptors CD44 and EGFR within lipid rafts [157, 158]. HAS2 is also involved in the development of lung 
fibrosis. Deletion of HAS2 abrogated the invasive fibroblast phenotype, impeded myofibroblast 
accumulation, and inhibited the development of lung fibrosis in a CD44-dependent manner [159]. In 
another study, it has been shown that HAS2 is important for TGF-β-induced mesenchymal  
differentiation and migration of NMuMG mammary epithelial cells in a CD44- and HA-independent 
manner [160]. 
 
Matrix Proteases 
Several proteolytic enzymes are involved in wound healing. MMPs belong to the metzincin family of 
metalloproteinase that present a zinc-binding motif at their active site. Plasminogen activators such as 
urokinase-type plasminogen activator (uPA) and tissue-type urokinase activator (tPA) are serine 
proteases. They are involved in the activation of plasminogen to plasmin and cleavage of fibrin polymers 
as well as degradation of various ECM components and activation of MMPs [2, 9]. MMPs are central 
players of healing process in the wound bed and are differentially expressed by all cell types in a time- 
and context-dependent manner. Apart from regulating ECM turnover, they control inflammation, cell 
migration and angiogenesis by acting on growth factors, cytokines, and cell surface receptors [161]. 
MMPs activity on various ECM components liberates active fragments called matrikines that regulate 
various cell functions during wound healing [12]. MMPs are involved in all phases of wound healing and 
their abnormal expression and functions are involved in dysfunctional wound repair and the 
development of chronic wounds or fibrosis, hypertrophic scars and keloids in skin. Scarless fetal wounds 
have a greater expression ratio of MMPs to TIMPs, which favors cell migration and ECM turnover 
compared to scarring wounds [162]. Chronic ulcers also exhibit increased activity of MMPs and other 
proteases [163]. It has been shown in a type 2 diabetic rat model that elevated MMPs expression is 
associated   with   delayed   wound   healing   and   development   of   diabetic   chronic   wounds    [164]. 
  
 
 
Hypertrophic scars are also characterized by constant MMPs activity [161]. For example, elevated MMP- 
9, and MMP-13 gene expression is observed in fibroblasts isolated from the margins of the original 
keloid wound and their expression is markedly downregulated upon treatment with decorin [165]. 
MMP-9 is recruited to the surface of fibroblasts and activates TGF-β signaling that in co-operation with 
other ECM signals promotes fibroblasts contraction, fibronectin expression and myofibroblast 
differentiation [166, 167]. On the other hand, the levels of MMP-1 are decreased in hypertrophic scar 
tissue and stimulation of MMP-1 expression reduces fibrosis and hypertrophic scars [168-171]. Wound 
closure is severely affected in mice deficient in MMP-8, and it is associated with a delay of neutrophil 
infiltration during the first days and a persistent inflammation at later time points [172]. MMP-8 acts as 
an anti-fibrotic protease due to the degradation of pro-inflammatory cytokines. Likewise, MMP-9 null 
mice display delayed wound healing associated with compromised re-epithelialization,  reduced 
clearance of fibrin clots and abnormal matrix deposition [173]. MMPs are important for re- 
epithelialization of various tissues in a tissue-dependent manner. For example, MMP-1 and MMP-7 are 
important for re-epithelialization in skin and mucosal epithelia, respectively, via different mechanisms 
involving integrin α2β1 [161]. Keratinocytes bind to collagen I in the dermis via integrin α2β1 upon 
basement membrane disruption in the wound bed. MMP-1 is induced in keratinocytes at the wound 
edge and cleaves collagen I. As a consequence, the collagen triple helix partially unwinds and reduces 
the avidity of integrin α2β1 ligation. This drives keratinocytes to interact via integrin α2β1 with intact 
collagen I within the open wound bed thus promoting keratinocyte migration [161, 174-176]. MMP-7 
expression is critical for re-epithelialization in mucosal epithelia. MMP-7 sheds syndecan-1 from 
epithelial cells, and this process attenuates the activation of integrin α2β1, thus decreasing its 
interaction with ECM components and facilitating cell migration [161, 177, 178]. 
 
Epigenetic reprogramming during wound healing 
In recent years, a large number of publications has focused on the area of epigenetic therapy, which is 
not surprising since it links alterations in chromatin structure to the cell phenotype and numerous 
functions of a given biological system [179, 180]. It is of fundamental and of great clinical relevance to 
perceive how these changes are orchestrated. Epigenetic regulation is an important driver of the wound 
healing response; however, many mechanistic details remain to be elucidated. Common and highly 
interdependent epigenetic mechanisms that are closely associated with gene expression include DNA 
methylation, post-transcriptional histone modifications and regulatory non-coding RNAs (ncRNAs) [181- 
185]. The dynamic interplay among these epigenetic mechanisms regulates chromatin remodeling and 
  
 
 
consequently can alter the expression status of large numbers of transcription factors and signal 
transduction molecules [182, 186, 187]. In this review, we focus our attention on the most extensively 
characterized subfamily of ncRNAs, named microRNAs, since they have been thoroughly studied among 
epigenome components in the context of wound healing and regenerative medicine [188]. They are 
endogenous small ncRNAs molecules, 17-25 nucleotides long, which have an important role in post- 
transcriptional regulation of a wide range of cellular processes [189]. Interestingly, more than 60% of 
protein-coding mRNAs may be targets of miRNAs as indicated by bioinformatics predictions, thus 
participating in various signal transduction pathways both in physiological and pathological conditions 
[190, 191]. The miRNA processing pathway has long been viewed as linear and universal to all 
mammalian miRNAs. As illustrated in Figure 2, this canonical maturation cascade includes the 
production of the 70-nucleotide primary miRNA (pri-miRNA) transcript, its cleavage to the precursor 
hairpin (pre-miRNA), transfer to the cytoplasm and finally the cleavage of the pre-miRNA to its mature 
length. The functional strand of the mature miRNA is loaded together with Argonaute proteins into the 
RNA-induced silencing complex (RISC), where it guides RISC to target mRNAs [192-195]. Depending on 
the complementarity, miRNAs can induce mRNA degradation via the RNA-induced silencing complex, 
translational repression, or total inhibition of mRNA translation [196, 197]. 
Epigenetic regulators appear to be involved in the wound healing and skin repair processes, thus 
dynamically regulating dermal regeneration. More specifically, wound healing and fibrosis are evidently 
regulated by a wide range of miRNAs, either in a direct or indirect way (Table 1). Individual miRNAs have 
been associated with distinct phases of wound healing, including inflammation, cell proliferation and 
tissue regeneration, serving themselves as target biomarkers for systematic regulation of wound repair 
and fibrosis [186]. For instance, miR-21 is the principal regulator of fibroblast migration and it inhibits 
the epithelialization in skin wound [198]. Moreover, it mediates fibroblast activation in pulmonary 
fibrosis, therefore it is characterized as a pro-fibrotic factor [199]. Self-limited and rigorously regulated 
inflammation is an initial step for proper wound repair, since chronic inflammatory responses may lead 
to overacting wound healing and loss of the regeneration process. Emerging evidence has shown that 
miRNAs may regulate inflammation through distinct mechanisms. For example, miR-146a abolishes the 
activation of the nuclear factor κB (NF-κB) pathway, which is the central signal transduction pathway of 
inflammation [200, 201]. Moreover, miR-146a induces the expression of the pro-inflammatory cytokine 
IL-10 and modulates the IL-1β signaling pathway [202, 203]. Recent reports indicate that miR-142-5p  
and miR-130a-3p may act as pro-fibrotic modulators by regulating macrophage functions via IL-4 and IL- 
3 expression [204]. Another interesting example is miR-29, which is linked to the pathogenesis of fibrosis 
  
 
 
by regulating ECM production and deposition and EMT. Its decreased expression in cardiac, renal, 
pulmonary and liver fibrosis, is followed by the upregulation of collagen type I and IV expression levels, 
affecting the severity of fibrosis in numerous organs [205-208]. Serum miR-29 levels are much lower in 
patients with advanced liver fibrosis compared to healthy controls [209]. Notably, the estradiol- 
stimulated miR-29 overexpression in liver cells of a mouse model may answer the question whether 
women are more susceptible to alcohol-induced liver fibrosis than men [210]. These findings suggest 
that miR-29 may act as an anti-fibrotic epigenetic modulator (Table 1), serving as a prognostic and 
potential therapeutic biomarker. Moreover, critical for the recovery of cells during wound healing is the 
cell proliferative phase, since it is necessary to rapidly restore an organ function. It has been reported 
that miR-203 may act as a pro-proliferative and pro-migratory factor in cutaneous wound healing and 
miR-483-3p controls keratinocyte proliferation during the re-epithelialization of wound healing process 
[211, 212]. To summarize, evidence suggests that miRNAs participate and regulate all phases of wound 
healing. Therefore, understanding the molecular context of their functions could be advantageous for 
tissue regeneration applications. 
 
Extracellular matrix regulation by miRNAs 
Considering the mechanism of miRNA function, which is based on the post-transcriptional regulation of 
RNA expression and translation (Figure 2), it is not surprising that they have been implicated in the 
regulation of ECM protein and glycan expression. Different modes of regulation have been described, 
including a direct targeting of ECM mRNAs, indirect regulation of ECM constituents via miRNA- 
dependent targeting of transcriptional activators and repressors, epigenetic regulation of ECM-targeting 
miRNAs, and co-regulation of miRNAs with ECM receptors (Figure 3) [247]. In addition, the pattern of 
miRNA expression within a given tissue and cell type can be regulated by via the 3′ UTR of selected ECM 
mRNAs, such as versican and CD44, and by matrix-mediated signaling processes [247-249]. In this 
section, these modes of regulation using selected examples of miRNA-dependent ECM molecules with 
relevance for wound repair are presented and critically discussed. 
Among the miRNAs directly regulating gene expression via induction of mRNA degradation through their 
3’UTR (Figure 2), the miR-29 family represents an important member targeting multiple ECM molecules. 
miR-29c downregulates two fibrillary collagens with particular importance for wound repair [216], 
collagen type I and type III [250-253], resulting in effects on cell motility and a modulation of cardiac 
fibrosis in different experimental models. miR-29 also plays a role in the regulation of proteolytic factors 
which are relevant during the phase of collagen remodeling and angiogenesis of skin wound repair. Both 
  
 
 
‘sheddases’ capable of releasing the extracellular domain of syndecans [126, 254] and MMPs processing 
fibrillary collagens, such as collagen I and collagen III, are of importance in this context. miR-29 is  
capable of directly targeting MMP-2 mRNA [122], whereas an indirect mode of MMP regulation by this 
miRNA has been described for aortic smooth muscle cells. Treatment of these cells with oxidized LDL 
resulted in miR-29b-mediated downregulation of DNA methyltransferase 3b [231]. The resulting 
epigenetic changes at lead to a differential regulation of MMP-2 and MMP-9. Finally, miR-29a/b/c co- 
regulates laminin LAMC2 and integrin α6 in head and neck squamous cell carcinoma [255], representing 
an example for a regulation of an ECM compound and its receptor by a miRNA [65, 256]. 
An additional multifunctional miRNA with relevance for ECM function is miR-10b. miR-10b mediates 
downregulation of the transcription factor HOXD10, resulting in an indirect upregulation of MMP-14 and 
uPA activator receptor (uPAR) in breast cancer and glioma cells [257, 258], thus influencing the 
proteolytic milieu. In addition, upregulation of miR-10b in breast cancer and endometriotic cells resulted 
in a direct targeting and downregulation of syndecan-1 as demonstrated by 3’ UTR luciferase reporter 
assays, qPCR, flow cytometry and immunofluorescence microscopy [259, 260]. In both cases, cell 
motility and invasive growth of the syndecan-1 depleted cells were affected, which could be attributed 
to a multitude of effects, including altered signaling via receptor tyrosine kinase, focal adhesion 
kinase/Rho and IL-6 signaling pathways as well as alterations in the proteolytic milieu that were due to 
reduced expression of this multifunctional co-receptor. miR-10b-dependent targeting of syndecan-1  
may be relevant to wound repair, as it regulates angiogenesis, wound re-epithelialization and 
recruitment of inflammatory cells during skin wound healing and cardiac repair [124, 126, 134]. 
Syndecans are also regulated by miR-143 and miR-145. Indeed, these miRNAs are thought to be 
functionally linked and co-regulated in a bicistronic manner [261]. miR-143 and miR-145 target 
syndecan-1, resulting in a reduction of cell growth in melanoma, urothelial carcinoma and ovarian 
cancer, respectively [262-264]. TGF-β-inducible miR-143 was also shown to target additional syndecan 
family members, including syndecan-4, involved in modulating fibroblast function during skin wound 
repair [127], and versican in a zebrafish model, where it had an impact on the glomerular filtration 
barrier [265]. Moreover, miR-143 and miR-145 have an impact on the proteolytic milieu, as evidenced  
by the regulation of MMP-13 [224] and the inhibitor PAI-1 [231], respectively. Syndecan-1 is a good 
example of a matrix receptor that can influence the expression of miRNAs and their respective targets. It 
acts upstream of some microRNAs, resulting in their altered expression. This was demonstrated in the 
case of prostate cancer cells, in which syndecan-1 silencing induced downregulation of the miRNA 
processing enzyme Dicer. The associated change in the levels of mature miR-331-3p and its targets 
  
 
 
resulted in the induction of EMT [266]. Moreover, aberrant syndecan-1 expression has been linked to 
the expression of miR-126 and in prostate cancer, with an impact on cell proliferation [267]. Finally, 
syndecan-1 has been identified as part of a regulatory loop comprised of MMP-9 and miR-494, which 
regulated irradiation-induced angiogenesis in medulloblastoma [268]. As recent reports indicate that 
syndecan-1 and the syndecan-processing enzyme, HPSE, are mechanistically involved in the biogenesis  
of exosomes [269, 270], it is tempting to speculate that this PG may also effect secretion of a multitude 
of miRNAs via this process. 
Collagens of the dermis play important roles by providing structural support for resident cells and for 
inflammatory and accessory cells during the remodeling phase of wound repair [271, 272]. Among the 
various collagen types found in vertebrates, the fibrillary collagens type I and type III play prominent 
roles during wound repair [272]. For example, direct regulation of collagen type I expression via binding 
of the miRNA seed sequence to the 3′ UTR of mRNAs encoding one of the three chains of these triple- 
helical structural proteins was demonstrated for let-7g (COL1A2), miR-29c (COL1A1, COL1A2) and miR- 
133a (COL1A1) [250-253], resulting in effects on cell motility and a modulation of cardiac fibrosis in 
different experimental models. Blood-derived fibrin and fibronectin form a provisional ECM in the initial 
stage of skin wound healing [272]. While a quantitative regulatory effect of miRNAs on these molecules 
at this stage appears unlikely considering the large quantities of blood-derived matrix proteins, miRNA- 
mediated modulation of fibronectin expression may be of importance at later stages of repair, affecting 
the migratory behavior of cells in the granulation tissue and wound edges. Indeed, several miRNAs have 
been shown to directly target fibronectin, resulting in altered cell survival and migration, including  miR- 
17 in a transgenic mouse model [273], miR-146a in diabetic animals [274], and miR-206 in 
bronchopulmonary dysplasia [275]. In several cases, the mesenchymal marker fibronectin is indirectly 
regulated via microRNAs affecting the process of EMT, as exemplified by the case of miR-200b in renal 
fibrosis [276] and miR-7 in breast cancer [277]. 
As a final example for regulatory modes exerted by ECM compounds and their receptors, the concept of 
competing endogenous RNAs, or ceRNAs is also discussed here. As a prime example, the 3’ UTR of 
versican mRNA acts as an endogenous microRNA sponge, thus sequestering miRNAs and neutralizing 
their activity. This has been shown by over-expression of versican 3’ UTR in diverse systems, resulting in 
a neutralization and target suppression of the microRNAs miR-199a [278] (regulating versican and 
fibronectin), miR-133a, miR-144 and miR-431 [279]. Of particular relevance for wound repair were 
experiments by Yang and Yee [108], who demonstrated enhanced wound closure and fibroblast 
migration in cells and transgenic mice expressing versican 3’ UTR. This phenotype was apparently due to 
  
 
 
binding of numerous miRNAs to the ceRNA, including miR-185, miR-203, miR-690, miR-680 and miR-434- 
3p, resulting in an upregulation of versican itself and of the Wnt signaling effector beta-catenin. Another 
example for a ceRNA is CD44. Interactions between this transmembrane receptor and its ligand HA 
regulate several aspects of wound repair, including chemotaxis and cell migration, collagen secretion, 
inflammation and angiogenesis [271]. CD44 mRNA acts as a ceRNA capable of neutralizing miRNAs, as 
has been shown miR-216a, miR-328, miR-330, miR-491, miR-512-3p, miR-608 and miR-671. As a 
consequence, the 3′ UTR of CD44 upregulated not only the expression of CD44 itself, but also of 
fibronectin and COL1A1, with possible relevance for wound repair [280, 281]. Moreover, CD44 is also 
directly targeted by several miRNAs including miR-34, miR-199a-3p, miR-328, miR-373 and miR-520c 
[282-285], resulting in effects on cell migration, proliferation and stem cell phenotype. Since it is a 
carbohydrate, expression of HA is not directly modulated by miRNAs, but via regulation of their 
biosynthetic enzymes, the HASes [286]. In breast and cervical cancer cells, inhibition of the miRNA let-7 
resulted in a suppression of its target HAS2, with an impact on cell survival, adhesion and invasive 
behavior [287]. Moreover, the targeting of HAS2 by miR-26b resulted in increased ovarian granulosa cell 
apoptosis [288], whereas targeting of HAS2 by miR-23a-3p caused cellular senescence, with possible 
implication for skin aging and repair [289]. Finally, the interaction of HA with CD44v3 in head and neck 
squamous cell carcinoma has been shown to have an indirect regulatory impact on the expression of 
miR-302 via pluripotency-associated transcription factor induction [290], providing another example for 
matrix-dependent signaling processes that regulate miRNA expression patterns. 
 
MicroRNA - ECM interactions in wound healing 
As mentioned above, wound repair is characterized by several successive phases, during which  
individual matrix molecules and miRNAs play distinct roles [291, 292] (Table 1, Figure 1). The earliest 
stage is characterized by hemostasis and inflammation. While it is unlikely that miRNAs play a role in 
regulating the amount of these largely blood-derived ECM molecules during the  hemostasis stage, it  
can be envisaged that the presence of these matrix constituents can influence the miRNA expression 
pattern in cells recruited to the wound (Figure 3). For example, the presence of thrombospondin-1 
affects the miRNA expression profile of vascular smooth muscle cells [293]. Platelet activation and 
degranulation subsequently trigger the recruitment of different classes of leukocytes as part of an early 
inflammatory response. A recent study on Staphylococcus aureus clearance at skin wound sites has 
revealed a role for miR-142-3p in neutrophil recruitment [294]. Using miR-142-3p-deficient mice, the 
authors   could   demonstrate   that   targeting   of   cytoskeletal   elements   and   Rho-GTPase    signaling 
  
 
 
compounds affected leukocyte recruitment. While not explored in this study, a targeting of integrin αν 
by this miRNA may impede recruitment of epithelial cells during wound repair by hindering cellular 
interactions with the ECM, including vitronectin, fibronectin and thrombospondin in the provisional 
wound matrix [295]. Likewise, altered expression of miR-223, which is upregulated in the inflammatory 
phase in human skin [296] could potentially affect β1 integrin expression and cell motility [297, 298], as 
well as myeloid-derived suppressor cell differentiation [299]. Another microRNA which is upregulated 
during early skin wound repair both in mouse models and humans is miR-155 [300, 301]. Apparently, an 
inhibition of miR-155 has beneficial effects on wound repair, as application of a miR-155-inhibitor 
reduced inflammatory cell recruitment into the wound and improved the structural quality of the 
regenerated tissue [302]. Likewise, miR-155-deficient mice showed more rapid and qualitatively 
improved wound repair, as evidenced by increased collagen I deposition [301]. In contrast, another 
study employing a miR-155 expression plasmid during cutaneous wound repair reported an acceleration 
of keratinocyte migration, which was attributed to an inverse regulation of MMP-2 and TIMP-1 [303]. 
The context-dependent effects may be due to the mode of experimental miR-155 modulation. In 
addition, additional targets of miR-155 may have contributed to the phenotype. Importantly, HPSE was 
shown to be regulated by a miR-155-based artificial miRNA, resulting in an inhibition of melanoma cell 
adhesion, migration and invasiveness [304]. Moreover, miR-155 regulates additional MMPs, which may 
have differentially affected wound repair in the partially conflicting studies [305]. 
At the late inflammatory stage of wound repair, inflammation needs to resolve, and several miRNAs 
contribute to this process (Figure 1). Notably, miR-21 is upregulated by macrophages upon phagocytosis 
of apoptotic neutrophils and contributes to the resolution of inflammation via the upregulation of anti- 
inflammatory cytokines such as IL-10 [306]. Expression of miR-21 is modulated by decorin during 
inflammation [307] and it has been shown to target the HS editing enzyme HSulf1, with a possible  
impact on HS-dependent signaling processes during wound repair [308]. Indeed, as pointed out before, 
both syndecans and decorin play a prominent role in wound repair and transgenic and knockout mouse 
models that display a wound healing phenotype [112, 124, 126, 127, 134]. Another miRNA involved in 
the resolution of inflammation during wound repair is miR-132, which is upregulated in several  
leukocyte subsets during the inflammatory phase of wound repair. While it primarily attenuates 
inflammation by promoting M2 polarization of macrophages and by preventing the overshooting 
production of pro-inflammatory cytokines [309, 310], the targeting of MMPs, such as MMP-9 and MT3- 
MMP/MMP-16 that was demonstrated in different experimental systems [311, 312], may additionally 
contribute to the resolution of inflammation in the context of wound repair. Since expression of  miR-99 
  
 
 
family members has been linked to the activity of several integrin subtypes, including β4 and ανβ3 
integrin [313, 314], it may be worth evaluating whether downregulation of miR-99a, miR-99b and miR- 
100 during the inflammatory phase is linked to altered integrin-ECM interactions [315]. Moreover, miR- 
146a, which is also downregulated during this phase of skin wound repair [316], may contribute to the 
resolution of inflammation as a negative regulator of several compounds of the proinflammatory NF-κB- 
pathway in keratinocytes and macrophages [317, 318]. miR-146a has also been described as a regulator 
of the PG aggrecan [319], reported to contribute to a block of dermal repair in ADAMTS-5-deficient mice 
via an effect of fibroblast differentiation from progenitor [320]. However, the relevance of this finding in 
the context of the inflammatory phase of wound repair is unclear. 
The shift in the cytokine profile linked to the differentiation of macrophages to a more reparative 
phenotype affects the proliferation of fibroblasts in the granulation tissue, the ECM production by these 
cells, and the induction of angiogenesis [291, 292]. Several miRNAs are upregulated during the phase of 
proliferation and re-epithelialization in skin wound repair (Figure 1). For example, miR-21 is upregulated 
in keratinocytes and mesenchymal cells of the wound edge, where it promotes cell migration [321, 322]. 
While it remains to be shown whether decorin, which has been linked to this miRNA [247] play a role in 
this process, it has been demonstrated that miR-21 inhibition does not only delay re-epithelialization 
and hinders contraction of the wound, but also affects collagen deposition, thus promoting cell adhesion 
and migration [321]. Another miRNA that is upregulated in proliferating keratinocytes is miR-31. While 
its mechanism of action involves a targeting of epithelial membrane protein-1 [323], it is noteworthy  
that miR-31 has been shown to target several integrin α subunits (α2-, α5, αν-) and β1-integrin in  
diverse experimental systems [324]. This suggests that integrin dysregulation may have additionally 
contributed to altered matrix-dependent cell spreading, collagen adhesion and proliferation. Likewise, 
downregulation of miR-99 family members may not only stimulate keratinocyte proliferation via 
upregulation of the miR-99-repressed signaling compounds Akt and mTOR [315], but also of several 
integrins [313, 314]. 
Angiogenesis is a pivotal aspect of the proliferative phase of wound repair, as it ensures a supply of 
nutrients for proliferating keratinocytes, fibroblasts and immune cells. ECM compounds such as pro- 
angiogenic integrins, MMPs and PGs such as versican, decorin and syndecans are important modulators 
of angiogenesis [112, 126, 325]. During skin wound repair, miR-199a-5p is downregulated in the dermis 
and endothelium, and it was shown that this miRNA inhibits angiogenesis via negative regulation of the 
transcription factor ETS1 [326], which is a known inducer of ECM proteins in fibroblasts, including 
collagen   I   α2,   TGF-β    induced   protein,   lumican   and   decorin    [327].   Moreover,       miR-199a-5p 
  
 
 
downregulation exerts a proangiogenic effect during wound repair via upregulation of MMP-1 [326].  
Like miR-199-5p, miR-200b targets ETS1 in addition to VEGFR2 [328]. As  miR-200b  also  regulates 
decorin [329] and fibronectin [276, 330] in other experimental systems, dysregulation of these ECM 
compounds may additionally contribute to the angiogenic process and wound re-epithelialization. 
Probably the most profound changes in miRNA-regulated ECM deposition are observed in the final 
remodeling phase of wound repair, during which collagen III is replaced by the structurally more stable 
collagen I under the influence of growth factors, such as TGF-β, which promote ECM synthesis [272, 
291]. A prominent miRNA involved in this process is miR-29b, which targets Col3α1, Col4α1, Col4α2 and 
Col5α1 [191, 331-333]. The relevance of miR-29b for wound repair become also apparent in a rodent 
wound model, were therapeutic application of this miRNA in a collagen scaffold increased the ration of 
collagens III and I. This was associated with a reduction of wound contraction and an overall 
improvement of remodeling [333]. Notably, miR-29b is known to target TGF-β, the integrin subunits α6 
and β1 and the MMPs MMP-2 and MMP-9, which may have additionally contributed to altered 
remodeling [255, 332, 334, 335]. An indirect impact of a miRNA on remodeling has been uncovered for 
miR-1908, which targets the protein SKI, a regulator of collagen synthesis [336]. miR-1908 increased 
scar-derived fibroblast proliferation and production of TGF-β and collagen I [337] and reduced scar 
formation in a rat model of wound repair [336]. In addition, application of miR-1908 inhibitors to burn- 
wound scars in rats reduced their size and fibrosis [337], suggesting that miR-1908 as a promising 
potential therapeutic target and tool in wound repair. 
The dysregulation of miRNAs’ expression and their ECM targets has been linked to wound healing 
complications, such as hypertrophic scarring, keloid formation, and chronic non-healing wounds [338]. 
The aforementioned miRNA miR-29b is one of 92 miRNAs which are differentially regulated between 
hyperplastic scars and normal skin [339]. In vitro data suggest an anti-fibrotic effect of this miRNA, as its 
upregulation in primary human endometrial stroma cells reduced expression of Col1α1 and αSMA, thus 
contributing to an apoptosis-induction and inhibition of myofibroblast-like cell proliferation [340]. 
Importantly, in a murine thermal injury model, it was downregulated in thermal injury tissue, whereas 
miR-29b treatment promoted wound repair and inhibited scar formation. At the molecular level, this 
improvement could be linked to inhibition of the TGF-β-SMAD-CTGF signaling pathway, resulting in a 
suppression of collagen deposition [341]. As discussed above, a targeting of integrins, LOX and MMPs 
may have additionally contributed to preventing overshooting repair and fibrosis in this context. The 
TGF-β-inducible miRNA, miR-145, is upregulated in hypertrophic scars compared to healthy skin [342]. 
miR-145 is known to influence the proteolytic milieu by downregulating PAI-1, ADAM-17 and the HSPG 
  
 
 
syndecan-1 [263, 343-345], and has been shown to influence ECM biosynthesis in cartilage by targeting 
the master regulator SOX9 [346]. In the context of hypertrophic scarring, the inhibition of collagen 
biosynthesis by PPARγ agonists is apparently due to a targeting of the TGF-β signaling mediator SMAD3 
by miR-145 [347]. Moreover, myofibroblasts subjected to miR-145 inhibition were characterized by a 
reduced expression of TGF-β1 and collagen I and decreased contractility and migration [342]. Another 
miRNA linked to altered TGF-β expression and hypertrophic scarring is miR-200b, an important 
modulator of EMT [348, 349]. miR-200b was shown to be downregulated in hypertrophic scar tissues 
and human hypertrophic scar fibroblasts and its downregulation in fibroblasts occurs in a TGF-β- 
dependent manner [330, 350]. Functional in vitro analysis revealed that this miRNA regulated apoptosis 
and proliferation of human hypertrophic scar fibroblasts by altering collagen I and III as well as 
fibronectin expression in a TGF-β-dependent manner [330]. Similarly, miR-143-3p expression is 
downregulated in hypertrophic scar tissues, and its upregulation in hypertrophic scar fibroblasts is 
associated with a reduction in collagen I, III and αSMA, due to CTGF targeting [351]. Another miRNA 
downregulated in hypertrophic scars is miR-185. Following bioinformatics target prediction analysis, 
miR-185 could indeed downregulate expression of TGF-β and collagen I in fibroblasts, affecting cell 
proliferation and apoptosis [352]. The proteolytic modulation of collagen function is regulated my 
miRNAs miR-10a and miR-181c, which affect this process in hypertrophic scar fibroblasts by targeting 
PAI-1 and uPA and increasing MMP-1 levels [353]. Hypertrophic scars exhibit a lower expression of the 
PG decorin compared to healthy tissue [354] and it has been shown that decorin reduces hypertrophic 
scarring by modulating TGF-β functions [355, 356]. Notably, miR-181b, a miRNA that is upregulated in 
hypertrophic scars, was shown to target decorin. The authors demonstrated that miR-181b inhibition in 
hypertrophic scar fibroblasts reversed not only TGF-β-mediated downregulation of decorin, but also 
myofibroblastic differentiation [357]. 
Keloids represent another form of excessive scarring, and miRNA-mediated dysregulation of ECM 
molecules has been shown to be involved in keloid formation [358]. Being defined as benign dermal 
scars capable of invading adjacent healthy tissue, their formation is due to aberrant production of ECM 
by fibroblasts [359]. Among the miRNAs involved in the regulation of collagen production are miR-7, 
miR-29a and miR-196a, which are downregulated in keloid fibroblasts and modulate collagen type I and 
III production [227]. Notably, inhibition of miR-7, which is also regulating fibronectin expression in other 
experimental systems [277], leads to increased collagen type I alpha 2 expression in dermal fibroblasts 
[360]. While the decorin-modulated miRNA miR-21 promotes keloid fibroblast proliferation [361, 362], 
miR-199-5p,  a  miRNA  targeting  MMPs  and  DDR1  [363],  inhibit  this  process.  Interestingly,  the 
  
 
 
upregulation of miR-21 in keloid keratinocytes resulted in the induction of an EMT-like process and an 
enhanced stem cell phenotype, which could be partially linked to an upregulation of the HA receptor 
CD44 [364]. Consequently, migration, invasion and sphere-forming abilities of keloid keratinocytes were 
enhanced, which suggests that aberrant expression of miR-21 may account for the invasion and 
recurrence of keloids. Overall, these data provide strong evidence for a role of dysregulated miRNA 
expression in overshooting collagen production in keloids. 
Another form of aberrant wound healing is associated with diabetes, as diabetic patients frequently 
suffer from impaired wound repair [365]. Indeed, the miRNA expression pattern in wound tissue of 
diabetic rats subjected to cutaneous wounding differs from their normal counterparts [366]. Among the 
differentially regulated miRNAs, miR-26a was shown to target the TGF-β signaling pathway compound 
SMAD1 [367], with an impact on the cell cycle and a potential impact on ECM biosynthesis. 
Consequently, miR-26a inhibition resulted in improved wound repair, including increased granulation 
tissue formation and angiogenesis. Interestingly, miR-26a also contributes to the progression of diabetic 
nephropathy in humans and mouse models through enhanced TGF-β/CTGF signaling, which results in 
altered collagen synthesis [368]. Similar to miR-26a, an angiogenesis-modulating effect was also 
observed in the case of miR-200b, which is upregulated in an TNF-α-dependent manner in diabetic mice, 
resulting in impaired angiogenesis [369], and possibly also altered expression of fibrillary collagens and 
fibronectin, as discussed above. Moreover, miR-155, is induced in wounds of diabetic mice, and its 
deficiency resulted in improved wound closure in knockout mice [301]. Apart from the identified targets 
BCL6, FIZZ1, RhoA, and SHIP1 it is noteworthy that miR-155 has also been linked to heparanase function 
[304], and is known to influence the proteolytic milieu via regulation of MMP-2 and TIMP-1 [303], which 
may have additionally influenced wound repair. Moreover, members of the miR-99 family are 
downregulated in diabetic wounds and may contribute to delayed repair via altering expression of 
several integrins or the PI3K/Akt signaling pathway, as discussed above [313-315]. Finally, inhibition of 
miR-146a in cultured human diabetic corneas was shown to have a beneficial effect on wound repair 
[236], however, it remains to be shown that its property of inhibiting fibronectin expression in tissues of 
diabetic animals [274] is linked to this phenomenon. miR-27b has been shown to target the matricellular 
proteins thrombospondin-1 and thrombospondin-2, which are important modulators of angiogenesis 
[370, 371]. In the context of diabetic wound repair and angiogenesis, it was shown that miR-27b 
upregulation in bone marrow-derived angiogenic cells promotes proliferation and survival, as well as 
tube formation, whereas therapeutic delivery of such miR-27b overexpressing into the wounds of 
diabetic mice  improved wound repair  [371]. Overall,  these  data  confirm a  role  for ECM-targeting   of 
  
 
 
miRNAs in diabetic wound repair complications, however, several potential targets with known 
functions in repair still need to be experimentally confirmed. 
Another area of tissue repair for which aberrant ECM regulation is a contributing factor is cardiac repair. 
Indeed, aberrant expression of syndecans, thrombospondins and MMPs, as well as altered fibrogenesis 
play major roles on this complex process [16, 134, 372]. With respect to altered miRNA dependent ECM 
regulation in myocardial infarction, both a direct impact on ECM synthesis and on proteolytic  
remodeling have been observed. Following the observation that the miR-29 family is dysregulated in 
myocardial infarction and targets numerous mRNAs encoding ECM proteins involved in cardiac fibrosis, 
van Rooij and coworkers demonstrated that miR-29 downregulation with anti-miRs in vitro and in vivo 
induces the expression of multiple collagens, whereas its over-expression in fibroblasts had the opposite 
effect [373]. Another miRNA, miR-24, was downregulated upon myocardial infarction in a rodent model, 
and its expression change was closely related to ECM remodeling [374]. Notably, in this study, lentivirus- 
mediated intramyocardial delivery of miR-24 improved heart function and attenuated fibrosis in the 
infarct border zone in vivo, which was ascribed to a targeting of the TGF-β processing enzyme furin, 
which in turn affected TGF-β-mediated ECM biosynthesis. Another in vivo study demonstrated that TGF- 
β1 and miR-21 were upregulated, whereas the inhibitor of TGF-β1-signaling, TGFβRIII was  
downregulated in the border zone of mouse hearts in response to myocardial infarction [375]. 
Importantly, miR-21 transfection into cardiac fibroblasts reduced TGF-βRIII expression and consequently 
increased collagen content. The authors demonstrated the presence of a reciprocal loop between miR- 
21 and TGF-βRIII in cardiac fibrosis in mice, and suggested targeting of this pathway as a novel new 
strategy for the prevention and treatment of myocardial remodeling [375]. 
Apart from regulating collagen expression, modulation of the proteolytic environment by miRNAs plays  
a role in cardiac remodeling. For example, in an ischemia-reperfusion model, miR-21 was shown to  
affect cardiac remodeling via upregulation of MMP-2 in a PTEN-dependent manner [376]. An increase in 
MMP-2 and MMP-9 activity was also observed in a mouse model, in which HMGB1 was injected in the 
peri-infarcted region of mouse failing hearts following coronary artery ligation. Notably, the authors 
found that HMGB1 upregulated miR-206, which in turn targeted the endogenous protease inhibitor 
TIMP-3, resulting in increased collagenolytic activity, enhanced left ventricular function and attenuated 
remodeling. Likewise, miR-17 was found to be upregulated in hearts of rodents subjected to myocardial 
infarction, and shown to 3' UTR of TIMP-2 and the protein-coding region of TIMP-1, thus promoting 
proteolysis in the infarcted tissue [377]. In a preclinical therapeutic approach, the authors could 
demonstrate  that  in  vivo  antago-miR  treatment  inhibiting  miR-17   enhanced  TIMP-1   and     TIMP-2 
  
 
 
expression, decreased MMP9 activity, reduced infarct size and improved cardiac function, suggesting 
miR-17 inhibition as a promising ECM-targeted approach for cardiac repair. Finally, miR-214 exerts a 
beneficial effect on cardiac remodeling, as it was shown that this miRNA increased the expression of 
collagen type I and III, of TGF-β1 and TIMP-1, whereas MMP-1 expression was decreased in cardiac 
fibroblasts subjected to AngII treatment [378]. These findings were corroborated in an in vivo model 
utilizing adenovirus-mediated delivery of miR-214. In summary, we conclude that there is strong 
evidence for a functional role of miRNA-mediated ECM remodeling in cardiac repair, and data in 
preclinical models show the therapeutic potential of miRNA and anti-miR-delivery in this setting. 
 
Novel therapeutic approaches: miRNA delivery strategies 
It is well established that miRNAs directly or indirectly regulate the expression and activity of ECM 
components. Recent data from our research group revealed that estrogen receptor β (ERβ) inversely 
regulates miR-10b and miR-145 expression in breast cancer cells. These miRNAs are critical modulators 
of the basic functional properties and the expression of ECM components in ERβ suppressed MDA-MB- 
231 breast cancer cells [379, 380]. These data imply that the efforts of miRNA targeting through ECM 
regulation must be more intense in order to manipulate the progression of various diseases. Recent 
advances in nanomedicine applied in several diseases contribute to overcome the limitations of the 
current therapeutic approaches. The markedly increased surface area of nanoparticles (NPs) in relation 
to their mass, surface reactivity and insolubility, the ability to agglomerate or change size in different 
media and enhanced endurance over conventional-scale substances, are some of their properties that 
make them attractive systems for several applications [381-384]. Since miRNAs have been identified as 
powerful mediators of wound healing , they are attractive candidates for a broad set of novel 
therapeutic strategies [385]. 
Depending on the mRNA-target miRNAs act either as gene suppressors or as inducers of miRNA 
expression. Therefore, in order to manipulate miRNA functions two targeting mechanisms have been 
developed: the pharmacologically active and synthetic double-strand miRNA mimics that restore miRNA 
expression and the oligonucleotide inhibitors or antago-miRs (known as anti-miRNAs) [386, 387]. Some 
of miRNAs characteristics include their small size, the known and conserved nucleotide sequence and 
the fact that one miRNA targets several mRNAs of a signaling pathway resulting in gene expression 
changes of its downstream targets in several biological processes. By this way, miRNAs act either as 
therapeutic agents or as therapeutic targets [388]. During their covalent conjugation with their carrier 
the cargo is released in the target cell through hydrolysis or reduction. This delivery system is very stable 
  
 
 
and can protect the miRNA in the bloodstream. The greatest advantage of miRNA therapy is the high 
biological half-lives of miRNA mimics or anti-miRs inside the cells, providing their functions even when 
they are absent for the plasma [389, 390]. These advantages of miRNA applications led to the definition 
of a new class of drug targets and introduced miRNA therapy as the future challenge for clinical 
applications. Viral vehicles show higher efficiency to of incorporating miRNAs, since they have been 
designed to provide improved transfection efficiency miRNA-mimics or anti-miRNAs. However, they are 
characterized by increased cytotoxicity and immune response [391]. On the other hand, non-viral miRNA 
delivery systems are characterized by lower toxicity and immunogenicity, increased cellular uptake, 
water solubility, resistance to endonucleases, and phagocytosis [385, 387]. Several non-viral delivery 
strategies, including lipid-based, polymer-based and inorganic miRNA vesicles, have been designed and 
are widely used in targeting approaches [392]. 
Polymer-based delivery systems have been extensively utilized as miRNA carrier and are based on the 
conjugation of the miRNA phosphate groups with the amine groups of cationic polymers, therefore 
protecting nucleic acids from degradation. Synthetic polymeric carriers include poly(lactic-co-glycolic 
acid) (PLGA), cell-penetrating peptide (CPP), poly (amidoamine) (PAMAM), polyethylenimine (PEI) and 
chitosan as delivery vectors [392, 393]. Conjugation with hydrophilic polyethylene glycol (PEG) could 
increase the conjugation efficacy and improve the half-live of the vehicle in serum [394]. Targeted 
delivery of anti-miR-21 and anti-miR-10b PLGA-PEG polymer NPs reduced tumor growth in a breast 
cancer cell model in vivo [395]. Moreover, PLGA-based polyplexes, encapsulated miR-26a with improved 
efficiency, which significantly increased the bone-healing capacity in an osteoporosis model [396], 
implying the importance of this nanocarrier in tissue engineering applications. miR-146 PEI-NPs inhibited 
the expression of pro-fibrotic and inflammatory signaling molecules, thus attenuating renal fibrosis in 
vivo [397]. Moreover, HA-based PLGA/PEI miR-145 nanocarrier facilitates cellular uptake and enhance 
miR-145 expression in colon cancer cells that was followed by a reduction of tumor progression in vitro 
[398]. 
Synthetic cationic liposomes are lipid-based nucleic acid delivery vehicles, widely used as carriers due to 
the encapsulation and intracellular dissolution of the miRNA cargo with increased efficiency and  
reduced off-target effects. The anionic miRNAs conjugated with the cationic liposome generates a net 
charge that can easily penetrate the cell membrane via endocytosis, allowing the miRNA mimic or anti- 
miRNA to target several mRNAs and manipulate their expression, thus achieving efficient cellular uptake 
[399]. For instance, miR-126 that promotes angiogenesis in vitro, has been loaded to polyethylene 
glycol-modified  liposomes  forming  the  so  called  bubble  liposomes,  and  its  systemic  delivery  to an 
  
 
 
ischemic fibrosis model resulted in the induction of the angiogenic factor VEGF and the improvement of 
blood flow [400]. A broad set of cationic lipososome miRNA nanocarriers have been designed and are 
extensively utilized in clinical applications. These include Lipofectamine (Invitrogen), DharmaFECT 
(Dharmacon), RNAi-MAX (Invitrogen), SilentFECT (Bio-Rad) and SiPORT (Invitrogen). The significance of 
their use is that these liposome formulations are biodegradable, bio-compatible, they have increased 
affinity to the cell surface and are non-pathogenic and non-immunogenic. The miRNA is released in the 
cytoplasm following intracellular dissolution of the particle [401]. 
Inorganic systems for delivering miRNAs have been developed since they exert high stability in vivo, 
antimicrobial properties, biocompatibility and low levels of cytotoxicity. These include gold NPs (AuNPs), 
silica NPs and Fe3O4-based NPs. An interesting example of AuNPs in a tissue regeneration application is 
their conjugation with the negatively-charged miR-29b, which resulted in improved efficiency of miR- 
29b to enter the cytoplasm and regulate osteogenesis, in low doses [402]. Another approach involves 
the conjugation of a nucleic acid to the Fab fragments of a cell-specific antibody. Antibodies are 
attractive vehicles for targeted delivery of miRNAs in vivo, since they exert high affinity and binding 
specificity [403, 404]. Nonetheless, in order to design a safe and efficient miRNA nanocarrier some 
concerns must be considered [403]. The most important issue is the anatomy of the targeted organ, 
however, the therapeutic dose, the tissue microenvironment and the ECM composition of each cell type 
must be evaluated in order to improve the therapeutic potential of the mimic miRNA or the anti-miRNA. 
Several miRNA nanocarriers for targeted therapy of fibrotic diseases have reached clinical development 
[386, 405]. The first miRNA nanocarrier that entered phase I clinical trials was a miR-34 mimic 
conjugated to liposomes (MRX34) for the treatment of multiple solid tumors (NCT01829971). EDVTM 
nanocells constitutes a novel delivery system for malignant pleural mesothelioma and non-small cell 
lung cancer treatment, which includes the intravenously administered EGFR (Vectibix® Sequence)- 
Targeted EnGeneIC Dream Vectors Containing miR-16 mimic (NCT02766699). Regarding wound healing 
in diabetic patients, the role miR-200b and miR-21 mimics will be evaluated in clinical trials 
(NCT02581098). The role of anti-miR-122 in chronic hepatic fibrosis (hepatitis C) is currently evaluated in 
different phase II clinical trials (NCT01646489, NCT01200420, NCT01872936, NCT02031133, 
NCT02508090). Finally, the impact of GalNAc-conjugated antimiR-103/107 on patients with type 2 
diabetes and non-alcoholic fatty liver diseases is evaluated in ongoing clinical trials (NCT02612662, 
NCT02826525). 
The novel nanosystems for miRNA delivery and the subsequent ECM manipulation are a  major  
challenge for novel therapeutic approaches and they  may improve the design and development of  safe 
  
 
 
and efficient miRNA carriers, which will serve in the diagnosis and therapeutic strategies to attenuate 
the progression of various diseases, including wound healing. 
 
Concluding remarks 
ECM is a highly orchestrated, dynamic network of non-cellular macromolecules that provide tissues and 
organs with structural stability and functionality. Apart from its role as scaffold of cells, ECM  
components dynamically interact to maintain cellular phenotype, thus serving as critical modulators of 
basic functional properties, such as proliferation, migration, angiogenesis and differentiation. Wound 
healing is an essential process of the proper tissue functioning and it is consisted of four distinct phases 
including hemostatic, inflammatory, proliferative and tissue remodeling phase. Despite the fact that 
wound healing is a strictly structured process, its de-regulation may result in the development of chronic 
wounds often associated with other comorbidities, including diabetes and the development of fibrosis 
and hypertrophic scars. An abundance of evidence has shown that epigenetic modifications participate 
in the regulation of this complex and systematic response. miRNAs are implicated in all wound healing 
phases through their direct or indirect interactions with ECM components, therefore they could be 
considered as mediators of this response. In recent years, several attempts for targeting miRNAs have 
been conducted in order to systematically deliver miRNAs in specific cell types and tissues. miRNA 
delivery via viral vehicles, synthetic polymer carriers, synthetic cationic liposomes and inorganic 
nanocarriers has yielded promising results in preclinical disease models, and several clinical trials for 
miRNA delivery have been initiated. The development of these delivery concepts may further develop 
the established clinical applications for patient management as well as the diagnosis and treatment of 
several diseases. 
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Figures Legends 
 
Figure 1. Schematic representation of wound healing phases. In each phase, the participation of ECM 
proteins is essential and its composition, mainly in the connective tissue, alters the hemostatic, 
inflammatory, proliferative and tissue remodeling phases of healing. Fibrin, fibronectin, platelets and HA 
bound to fibrinogen, vitronectin, factor XIIIα and other clotting proteins are major constituents during 
the hemostatic phase of the wound. As leukocytes migrate into the wound site, they release proteases 
to degrade the fibrin-rich ECM. Immune cells secrete a broad range of inflammatory cytokines and 
growth factors to attract stromal cells to migrate into the wound. Several matrix-stored growth factors 
(i.e. PDGF, EGF, TGF-β) and PGs released and secreted from endothelial cells (i.e. syndecans, decorin, 
lumican) are also displaced. In the next phase, stromal fibroblasts migrating into the wound area 
(arrows) produce a provisional ECM characterized by the presence of fibronectin, matricellular proteins, 
decreased protease activity, fibrillar (type I, III) and non-fibrillar (type IV, VI, VII) collagen, and growth 
factors (i.e. EGF, FGF, TGF-β). The secreted matrix PGs (i.e. decorin, lumican) and collagen that are 
associated with mature healing wounds are secreted by keratinocytes and leukocytes to promote 
proliferation and migration of vascular components, endothelial and epithelial cells. During the tissue 
remodeling phase, the stiffer matrix and several growth factors (i.e. TGF-β) trigger stromal cells to 
induce wound contraction by adopting a myofibroblast phenotype. The supportive ECM is enriched in 
matrix PGs, proteases and realigned collagen type I cross-linked fibers. The final step in wound repair 
involves the formation of overly aligned collagen fibers that regain almost 80% of the primary tissue 
functionality. The lower panel demonstrates a summary of the most critical miRNAs that are involved in 
each wound healing phase and manipulate crucial cell functions, such as fibrillogenesis in the connective 
tissue, proliferation, migration, angiogenesis and tissue remodeling. Arrows indicate up- or 
downregulation of miRNA expression. 
 
Figure 2. The canonical mechanism of miRNA biogenesis and post-transcriptional gene silencing. The 
initiation step is the formation of 70-nucleotide pri-miRNA by the RNA polymerase II and III in the 
nucleus. Pri-miRNA is cleaved by the Drosha complex and the resulting pre-miRNA, which has a short 
stem plus a ~2-nucleotide 3' overhang is recognized by the exportin-5 complex and is exported to the 
cytoplasm, where it is cleaved by the Dicer complex to the mature miRNA duplex. The miRNA passenger 
strand is degraded and the mature miRNA strand (17-25 nucleotides), together with Argonaute proteins 
(Ago2)   guides   the   RISC   to   bind   the   3’   UTR   region   of   the   target   mRNA.   Depending   on  the 
  
 
 
complementarity of the seed sequence of the miRNA and its cognate mRNA, miRNA binding to the 3’ 
UTR site destabilizes the mRNA-target. This process may result in mRNA degradation, translational 
repression or mRNA deadenylation (not shown). Novel delivery strategies involve the encapsulation of 
miRNA nucleic acids (mimics or anti-miRs) into bio-degradable liposome formations, which are 
characterized by improved stability, high affinity, and low toxicity. These nanocarriers may serve as 
diagnostic tools and therapeutic strategies in several clinical applications. 
 
Figure 3. miRNA-mediated ECM targeting is a critical regulator of basic functional properties, such as cell 
proliferation, differentiation, migration and survival. The production of pri-miRNA in the nucleus is 
followed by its export to the cytoplasm and its further cleavage to the mature miRNA, which targets 
specific mRNAs. Here, representative examples of functional relationship between miRNAs and major 
ECM components participating in wound healing are shown. 
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Table 1. Targets and main actions of major miRNAs linked to wound healing and fibrosis in clinical indications. 
 
 
TGFβ/SMAD7 
human skin wounds (skin fibrosis); mediates fibrogenic 
activation (pulmonary fibrosis) 
 
 
miR-29 Collagen      I      &     IV,     PDGF, 
TGFβ1/SMAD2/SMAD3, fibrillin, 
elastin, profibrotic genes, Wnt/ 
Frizzled/ β-catenin, PI3K/AKT, 
αSMA, fibronectin, ITGB1, IGF-I, 
PDGFR-β, TGFβ1/ PI3K/AKT, 
TNF-α/NF-κB 
Antifibrotic function in cardiac fibroblasts (cardiac 
fibrosis); negatively related to the severity of the 
fibrosis in human fetal lung fibroblast (pulmonary 
fibrosis); antifibrinogenic mediator through the 
inhibition of collagen I&ΙV expression, induced by 
TGFβ1, and its deposition in the liver (kidney & hepatic 
fibrosis); high glucose or TGFβ stimulation 
downregulates miR-29 expression and promotes 
collagen formation (renal fibrosis) 
Anti-fibrotic [219-227] 
 
 
miR-30a TET1, Snai1 Decrease in the degree of myocardial  fibrosis (cardiac 
fibrosis); blocks mitochondrial fission (pulmonary 
fibrosis); EMT inhibition in vitro & in vivo (diabetic & 
peritoneal fibrosis) 
Anti-fibrotic [228-231] 
microRNA Predicted Targets Putative Action(s) Effect References 
let-7d HMGA2, TGFβ/SMAD3 Attenuates EMT in vitro & in vivo; reverses fibrotic 
phenotype (pulmonary fibrosis) 
Anti-fibrotic [213-215] 
miR-10b PTEN, HOXD10 Mediates TGF-β-dependent EMT (myocardial & skin 
fibrosis) 
Anti-fibrotic [216, 217] 
miR-21 EGR3, vinculin, LepR, Fibroblast migration; delay in epithelialization in acute Pro-fibrotic [198, 199, 218] 
 
 
 
 
 
 
miR-203 Ran, Raph1 Pro-proliferative and pro-migratory factor in 
cutaneous wound healing; suppresses hepatic fibrosis 
Anti-fibrotic [212, 243] 
miR-130a-3p LepR, PPARγ, Delayed   epithelialization   in   an   acute   human  skin Anti-fibrotic [198, 204] 
  wound model (skin fibrosis); mediator of 
macrophage’s fibrogenesis 
  
miR-142-5p SOCS1/STAT6 Regulates macrophage profibrogenic gene expression 
in chronic inflammation via IL-4/ IL-13 mediation 
Pro-fibrotic [204] 
miR-145 TNFRSF11B, KLF4 Inhibits cell proliferation and fibrosis  (articular 
fibrosis); promotes fibroblast trans-differentiation 
(pulmonary fibrosis); TGF-β1-stimulated myofibroblast 
differentiation & activation (corneal fibrosis) 
Anti-fibrotic [232-234] 
 
miR-146a 
 
αSMA, SMAD4 
 
Represses pro-inflammatory cytokines within the 
wound (corneal fibrosis); negatively regulates the 
osteogenesis and bone regeneration in vitro & in vivo 
 
Anti-fibrotic 
 
[235-237] 
 
miR-181α 
 
PHLPP2 
 
Enhanced keloid fibroblast DNA synthesis and 
proliferation and inhibited apoptosis (skin fibrosis) 
 
Pro-fibrotic 
 
[238] 
miR-181-5p STAT3, Bcl2 Activation of autophagy (liver fibrosis) Anti-fibrotic [239] 
miR-200 TGFβ2, ZEB1/2 Decreases TGF-β signaling and TGF-β-dependent EMT 
(liver & renal fibrosis) 
Anti-fibrotic [240-242] 
 
 
 
 
 
miR-214-5p CTGF, TGFβ Increased MMP2, MMP9 expression levels; hepatitis-C Anti-fibrotic [244-246] 
  induced    liver    fibrosis;    hepatic    remodeling  (liver  
 
 
miR-483-3p 
 
 
Cell proliferation protein MKi76, 
fibrosis) 
 
Control    keratinocyte    proliferation,   growth   arrest Anti-fibrotic 
 
 
[211] 
the kinase MK2 and a 
transcription 
factor YAP1 
during re-epithelialization, promotion of wound 
healing in vitro & in vivo 
 
 
 
 
 
Abbreviations: Bcl2, B-cell lymphoma 2; Col1A1, collagen type I alpha 1; Col3A1, collagen type III alpha 1; Col4A1, collagen type IV alpha 1; EGR, 
early growth response factor; EMT, epithelial-to-mesenchymal transition; HMGA2, high-mobility group AT-hook 2; IGF-I, insulin-like growth 
factor I; ITGB1, integrin β1; KLF4, Kruppel-like factor 4; LepR, leptin receptor; MMP, matrix metalloproteinase; PDGFR, platelet-derived growth 
factor receptor; PHLPP2, PH domain leucine-rich repeat protein phosphatase 2; PI3K, phosphoinositide 3-kinase; PPARγ, peroxisome 
proliferator-activated receptor γ; PTEN, phosphatase and tensin homolog deleted on chromosome 10; Ran, Ras-related Nuclear  protein; 
Raph1, Ras-associated and pleckstrin homology domains-containing protein 1; αSMA, alpha smooth muscle actin; SMAD, mothers against 
decapentaplegic homolog; Snai1, snail family transcriptional repressor 1; SOCS1, suppressor of cytokine signalling 1; STAT6, signal transducer  
and activator of transcription 6; TGF, transforming growth factor; TET1, ten-eleven translocation 1; TNF-α, tumor necrosis factor alpha; 
TNFRSF11B, tumor necrosis factor receptor superfamily member 11b 
  Highlights 
• Extracellular matrix (ECM) plays regulatory roles in cell functions, tissue regeneration and remodeling. 
• The interplay between ECM and resident cells exerts its critical role in many aspects of wound healing, matrix degradation and biosynthesis. 
• Epigenetic regulatory mechanisms, such as the endogenous non-coding microRNAs (miRNAs) drive the wound healing response and dermal regeneration. 
• miRNAs have pivotal roles in ECM composition (matrix proteins, proteoglycans and proteases) during wound healing, serving themselves as target biomarkers for systematic regulation of wound repair. 
• miRNAs targeting and the delivery strategies designed for clinical applications are emerging areas of research with clinical relevance. 
